港股创新药企云顶新耀“摘B”成功

Core Viewpoint - CloudTop New Drug Technology Co., Ltd. has received approval from the Hong Kong Stock Exchange to remove the "B" mark from its stock code, signaling strong profitability and growth potential to the capital market [2] Group 1: Financial Performance - In 2024, the company reported a total revenue of 707 million yuan, representing a year-on-year growth of 461%, and achieved annual profitability for the first time at the commercial level [2] Group 2: Strategic Initiatives - The company is deepening its "dual-drive" strategy by introducing overseas products while focusing on self-research and authorized introduction in high-value "blue ocean" areas [2] - CloudTop is actively advancing its differentiated pipeline layout for self-research and global rights products [3] Group 3: Product Development - The company's self-developed next-generation covalent reversible BTK inhibitor, EVER001, has shown positive clinical data, with global development progressing steadily [3] - The personalized tumor therapeutic vaccine EVM16 has entered the clinical stage, with the first patient treated in March this year [3] - The universal spot tumor therapeutic vaccine EVM14 has received FDA approval for its new drug clinical trial application, marking it as the company's first self-developed mRNA tumor therapeutic vaccine to enter global clinical stages [3] - The self-generated CAR-T project is expected to complete its first preclinical candidate drug screening this year [3]